Varicella-zoster virus: Another trigger of guillain-barré syndrome?

Clinical Infectious Diseases

Volumn 51, Issue 5, 2010, Pages 531-533

  Lehmann, Helmar C ^a   Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ASSOCIATION; GUILLAIN BARRE SYNDROME; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; VARICELLA ZOSTER VIRUS;

GUILLAIN-BARRE SYNDROME; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; RISK FACTORS;

EID: 77955833050     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655137     Document Type: Note

References (39)

1. Hughes RA, Cornblath D.R. Guillain-Barré syndrome. Lancet 2005; 366(9497):1653-1666.
2. Kieseier BC, Hartung HP,Wiendl H. Immune circuitry in the peripheral nervous system. Curr Opin Neurol 2006; 19(5):437-445.
3. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30(2):131-156.
4. Lehmann HC, Meyer zu Hörste G, Kieseier BC, Hartung HP. Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Dis 2009; 2:261-281.
5. van Doorn PA, Ruts L, Jacobs B.C. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008; 7(10):939-950.
6. Meyer zu Horste G, Hu W, Hartung HP, Lehmann HC, Kieseier B.C. The immunocompetence of Schwann cells. Muscle Nerve 2008; 37(1):3-13.
7. Willison H.J. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 2005; 10(2):94-112.
8. Yuki N, Odaka M. Ganglioside mimicry as a cause of Guillain-Barré syndrome. Curr Opin Neurol 2005; 18(5):557-561.
9. Jacobs BC, Rothbarth PH, van der Meche FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998; 51(4):1110-1115.
10. Asbury AK, Arnason BG, Adams R.D. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969; 48(3):173-215.
11. Hartung HP, ToykaK.V. T cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol 1990; 27(suppl):S57-S63.
12. Jung S, Kramer S, Schluesener HJ, Hunig T, Toyka K, Hartung HP. Prevention and therapy of experimental autoimmune neuritis by an antibody against T cell receptors-a/b. J Immunol 1992; 148:3768-3775.
13. Willison HJ, Yuki N. Peripheral neuropathies and antiglycolipid antibodies. Brain 2002; 125(pt 12):2591-2625.
14. Ho TW,Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999; 45(2):168-173.
15. Sheikh KA, Deerinck TJ, EllismanMH, Griffin J.W. The distribution of ganglioside-like moieties in peripheral nerves. Brain 1999; 122 (pt 3):449-460.
16. Gong Y, Tagawa Y, LunnMP, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 2002; 125(pt 11):2491-2506.
17. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001; 49(6):712-720.
18. Sheikh KA, Zhang G, Gong Y, Schnaar RL, Griffin J.W. An antiganglioside antibody-secreting hybridoma induces neuropathy in mice. Ann Neurol 2004; 56(2):228-239.
19. Goodfellow JA, Bowes T, Sheikh K, et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci 2005; 25(7):1620-1628.
20. Kang J-H, Sheu J-J, Lin H-.C. Increased risk of Guillain-Barré syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis 2010; 51(5):525-530 (in this issue).
21. Hadden RD, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001; 56(6):758-765.
22. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain- Barré syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009; 169(3):382-388.
23. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993; 178(5):1771-1775.
24. Yuki N, Taki T, Takahashi M, et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994; 36(5):791-793.
25. Ang CW, Jacobs BC, Brandenburg AH, et al. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome. Neurology 2000; 54:1453-1458.
26. Steiner I, Kennedy P, Pachner A. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol 2007; 6(11):1015-1028.
27. Kilgore P, Kruszon-Moran D, Seward J, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003; 70(suppl 1): S111-S118.
28. Thiry N, Beutels P, Shkedy Z, et al. The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 2002; 161(11):588-593.
29. Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine 2001; 20(1-2):121-124.
30. Hughes RA, Hadden RD, Gregson NA, Smith K.J. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 1999; 100(1-2):74-97.
31. Levin M, Smith J, Kaufhold R, et al. Decline in varicella-zoster virus (VZV)-specific cellmediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188(9):1336-1344.
32. Miller A. Selective decline in cellular immune response to varicella-zoster in the elderly.Neurology 1980; 30(6):582-587.
33. Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981; 32(1):24-27.
34. Burke B, Steele R, Beard O, Wood J, Cain T, Marmer D. Immune responses to varicellazoster in the aged. Arch Intern Med 1982; 142(2):291-293.
35. Oxman M. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009; 109(6 suppl 2):S13-S17.
36. Press R, Mata S, Lolli F, Zhu J, Andersson T, Link H. Temporal profile of antiganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome. J Neurol Sci 2001; 190(1-2):41-47.
37. Haanpää M, Nurmikko T, Hurme M. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scand J Infect Dis 2002; 34(2):112-114.
38. Cho J, Shin D, Lee K. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea. J Dermatol Sci 2007; 45(3):213-215.
39. Thomas S, Hall A. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4(1):26-33.